These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24988935)

  • 41. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Drug interactions in medical oncology].
    Ishiguro H; Koshiji M; Morizane T; Taniai H; Enatsu S; Fujimoto T; Nambu Y
    Gan To Kagaku Ryoho; 2009 May; 36(5):879-85. PubMed ID: 19461200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
    Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
    Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tyrosine kinase inhibitors in pediatric malignancies.
    Skolnik JM; Adamson PC
    Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinically relevant drug interactions with multikinase inhibitors: a review.
    Hussaarts KGAM; Veerman GDM; Jansman FGA; van Gelder T; Mathijssen RHJ; van Leeuwen RWF
    Ther Adv Med Oncol; 2019; 11():1758835918818347. PubMed ID: 30643582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel tyrosine kinase inhibitors for renal cell carcinoma.
    Dorff TB; Pal SK; Quinn DI
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases.
    Hulin A; Gelé T; Fenioux C; Kempf E; Sahali D; Tournigand C; Ollero M
    Clin J Am Soc Nephrol; 2024 Jul; 19(7):927-938. PubMed ID: 38079278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.
    Rowland A; van Dyk M; Mangoni AA; Miners JO; McKinnon RA; Wiese MD; Rowland A; Kichenadasse G; Gurney H; Sorich MJ
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):31-49. PubMed ID: 27561659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic drug interactions with anticancer drugs.
    Loadman PM; Bibby MC
    Clin Pharmacokinet; 1994 Jun; 26(6):486-500. PubMed ID: 8070221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors.
    Willemsen AE; Lubberman FJ; Tol J; Gerritsen WR; van Herpen CM; van Erp NP
    Drug Discov Today; 2016 Jun; 21(6):962-76. PubMed ID: 26995271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.